Prestige Brands earnings
This article was originally published in The Tan Sheet
The weak cough/cold season and industry's voluntary removal of some pediatric cough/cold products contributed to a 1 percent drop in Prestige Brands Holdings' third-quarter revenues to $45.1 million compared to the prior-year period, the consumer products firm says Feb. 8. Prestige Brands also notes "competitive pressures on the Doctor's NightGuard dental protector" contributed to the decline. However, strong sales of the Murine brand and Clear Eyes helped soften the cough/cold revenue losses. Despite these problems, the company's overall third-quarter revenue is slightly ahead of the previous year's by $100,000 for a total of $80.2 million in the quarter...
You may also be interested in...
Fractyl Health closed a $100m financing round to support ongoing development of duodenal mucosal resurfacing (DMR) technology that addresses root causes of type 2 diabetes. CEO Harith Rajagopalan spoke of his hopes for the technology.
The ‘sea change’ inside White Oak should be seen as very encouraging for sponsors, FDA official says.
Foreign facility visits may take longer to reach usual levels because of the ongoing coronavirus outbreaks in other countries.